STOCK TITAN

iRhythm Holdings approves buyback of up to $200M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

iRhythm Holdings, Inc. (IRTC) said its board approved a share repurchase program on November 10, 2026, authorizing purchases of up to $200.0 million of its outstanding common stock. Repurchases may be made in the open market, in privately negotiated transactions, through accelerated share repurchase transactions, or by other methods. The amount and timing are at the company’s discretion, depending on market conditions and corporate needs.

Open-market repurchases will be structured to occur in accordance with applicable federal and state securities laws, including Rule 10b-18 pricing and volume conditions. The company may also enter into Rule 10b5-1 plans to facilitate repurchases. It expects to use existing cash and cash equivalents and ongoing cash from operations. The program does not require purchases of any particular amount or share count and may be modified, suspended, or terminated at any time by the board; the company stated repurchases may not occur in the expected timeframe or manner, or at all.

Filing Explained

The board authorized up to $200 million for repurchases, but committed to no purchases; if used, the company would spend cash to buy outstanding common stock. At September 30, 2026, iRhythm reported $394.718 million in cash and cash equivalents, a liquidity reference point rather than a stated repurchase amount.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Share repurchase authorization Up to $200.0 million Board-approved program for outstanding common stock
accelerated share repurchase transactions financial
"through accelerated share repurchase transactions or by other methods"
A way for a company to buy back a large number of its own shares immediately by contracting with a bank that delivers the stock up front and then fills the trade over time. It matters to investors because it quickly reduces the number of shares outstanding—similar to a store buying back its own coupons to raise the value of each remaining coupon—which can raise profit per share, signal management’s confidence, and change the company’s cash and debt picture.
Rule 10b-18 regulatory
"including within the pricing and volume conditions of Rule 10b-18"
Rule 10b-18 is a regulation that sets strict rules for how a company's executives and employees can buy back their own company's stock from the market. It helps ensure that these buybacks happen in a fair and transparent way, reducing the chance of market manipulation. This is important for investors because it offers protection against unfair practices and promotes confidence in the integrity of the stock market.
Rule 10b5-1 plans regulatory
"enter into Rule 10b5-1 plans to facilitate repurchases"
A Rule 10b5-1 plan is a prearranged schedule that lets company insiders buy or sell stock at set times or prices, set up when they do not possess confidential information. It acts like an automatic thermostat for trades, reducing the risk that otherwise-timed transactions could be accused of insider trading. Investors care because such plans increase transparency about insider activity and signal when insider trades are routine rather than reactive to private news.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much stock did IRTC authorize itself to repurchase?

iRhythm’s board authorized purchases of up to $200.0 million of outstanding common stock. The authorization does not require the company to repurchase any particular dollar amount or number of shares, and the board may modify, suspend, or terminate the program at any time.

How will IRTC carry out and fund the repurchases?

The company may buy shares in the open market, in privately negotiated transactions, through accelerated share repurchase transactions, or by other methods. Open-market repurchases will be structured to follow applicable securities laws, including Rule 10b-18 pricing and volume conditions. iRhythm expects to use existing cash and cash equivalents and ongoing cash from operations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001388658 0001388658 2026-11-10 2026-11-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 

FORM 8-K

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): November 10, 2026

 

iRhythm Holdings, Inc. 

(Exact name of Registrant as specified in its charter) 

 

Delaware 001-37918 41-3421287
(State or other jurisdiction of
incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification Number)

 

699 8th Street, Suite 600 

San Francisco, California 94103

(Address of principal executive office) (Zip Code)

 

(415) 632-5700 

(Registrant’s telephone number, including area code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share IRTC The NASDAQ Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 7.01. Regulation FD Disclosure.

 

On November 11, 2026, iRhythm Holdings, Inc., a Delaware corporation (the “Company”), issued a press release announcing the share repurchase program described under Item 8.01 below. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Item 7.01, including Exhibit 99.1 to this Current Report on Form 8-K, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 8.01. Other Events.

 

On November 10, 2026, the board of directors of the Company approved a share repurchase program with authorization to purchase up to $200.0 million of the Company’s outstanding common stock.

 

Repurchases under the program may be made in the open market, in privately negotiated transactions, through accelerated share repurchase transactions or by other methods, with the amount and timing of repurchases to be determined at the Company’s discretion, depending on market conditions and corporate needs. Open market repurchases will be structured to occur in accordance with applicable federal and state securities laws, including within the pricing and volume conditions of Rule 10b-18 under the Exchange Act. The Company may also, from time to time, enter into Rule 10b5-1 plans to facilitate repurchases of its shares under this authorization. This program does not obligate the Company to repurchase any particular dollar amount or number of shares of common stock and may be modified, suspended or terminated at any time at the discretion of its board of directors. The Company expects to fund repurchases with existing cash and cash equivalents and ongoing cash from operations.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the amount, timing, methods and sources of funding of repurchases under the share repurchase program and the structure of such repurchases. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual events or results to differ materially from those expressed or implied by the forward-looking statements, including, but not limited to, risks relating to the fact that common stock repurchases may not be conducted in the timeframe or in the manner the Company expects, or at all, and the important factors discussed under the caption “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission (the “SEC”) on November 5, 2026, and the Company’s other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this Current Report on Form 8-K. Any such forward-looking statements represent management’s estimates as of the date of this Current Report on Form 8-K. While the Company may elect to update such forward-looking statements at some point in the future, the Company disclaims any obligation to do so, even if subsequent events cause its views to change.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit No.     Description
99.1   Press release issued by iRhythm Holdings, Inc., dated November 11, 2026.
104   Cover Page Interactive Data File (formatted as Inline XBRL)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IRHYTHM HOLDINGS, INC.
     
Date: November 12, 2026 By: /s/ Daniel Wilson
    Daniel Wilson
    Chief Financial Officer

 

 

 

 

 

Exhibit 99.1 

 

 

 

iRhythm Announces Approval of $200 Million Share Repurchase Program

 

SAN FRANCISCO, November 11, 2026 - iRhythm Holdings, Inc. (Nasdaq: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease, today announced that on November 10, 2026, its Board of Directors approved a share repurchase program with authorization to purchase up to $200 million of the company’s outstanding common stock.

 

The approval reflects iRhythm’s confidence in the continued strength of its core business, as well as its significant new growth opportunities from the addition of the recently acquired VitalConnect business.

 

Repurchases under the program may be made in the open market, in privately negotiated transactions, through accelerated share repurchase transactions or by other methods, with the amount and timing of repurchases to be determined at the company’s discretion, depending on market conditions and corporate needs. Open market repurchases will be structured to occur in accordance with applicable federal and state securities laws, including within the pricing and volume conditions of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The company may also, from time to time, enter into Rule 10b5-1 plans to facilitate repurchases of its shares under this authorization. This program does not obligate the company to repurchase any particular dollar amount or number of shares of common stock and may be modified, suspended or terminated at any time at the discretion of its Board of Directors.

 

The company expects to fund repurchases with existing cash and cash equivalents and ongoing cash from operations.

 

About iRhythm Holdings, Inc.

 

iRhythm is a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to deliver better data, better insights, and better health for all. For more information, visit www.irhythmtech.com.

 

 

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future actions or operating or financial performance. In particular, these statements include, without limitation, statements regarding the amount, timing, methods and sources of funding of repurchases under the share repurchase program and the structure of such repurchases, as well as statements regarding the continued strength of our core business and growth opportunities from the VitalConnect acquisition. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: risks relating to the fact that common stock repurchases may not be conducted in the timeframe or in the manner we expect, or at all; risks relating to our ability to successfully integrate the VitalConnect business and realize the anticipated benefits of the acquisition; intense competition in the markets we compete in; fluctuations in our operating results; future reimbursement and regulatory conditions; financial market conditions; the execution and effect of our business strategy; future business decisions made by us and our competitors; and additional risks described in the section entitled “Risk Factors” and elsewhere in our filings made with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed on November 5, 2026. These forward-looking statements speak only as of the date of this press release and should not be unduly relied upon. We undertake no obligation to update them except as required by law.

 

Investor Contact

 

Francis Pruell

investors@irhythmtech.com

 

Media Contact

 

Kassandra Perry

mediarelations@irhythmtech.com

 

 

 

Filing Exhibits & Attachments

4 documents

Keep reading